BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK ...
New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly ...
Abbisko Therapeutics (HKEX: 02256) announced that the company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research ...
Morning Overview on MSN
MSK study shows mutated cells reshape nearby tissue early, helping tumors take hold
A single genetic mutation in a lung cell can start rewriting the rules for the tissue around it almost immediately, ...
The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...
MedPage Today on MSN
Next-Generation KRAS G12C Inhibitor Shows 'Robust' Efficacy in Advanced Lung Cancer
Responses observed in patients with and without previous exposure to other KRAS G12C inhib ...
At AACR, more strong results for Revolution Medicine’s KRAS drug, plus assurance from NCI’s director
At AACR, Revolution Medicines presented more eye-catching data about its KRAS-targeting treatment, and Anthony Letai declared ...
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...
BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering ...
MedPage Today on MSN
Novel KRAS Drug Shows 'Excellent' Efficacy in Tough-to-Treat Lung Cancer
Zoldonrasib ideal for further evaluation in KRAS G12D-mutant disease, expert says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results